VCEL - Vericel Corporation
18.59 +0.21 (1.14%)
Pre-Market: 7:00AM EST
| Previous Close | 18.50 |
| Open | 18.48 |
| Bid | 18.15 x 1200 |
| Ask | 19.24 x 1800 |
| Day's Range | 18.24 - 18.68 |
| 52 Week Range | 13.40 - 21.01 |
| Volume | 283,719 |
| Avg. Volume | 470,026 |
| Market Cap | 821M |
| Beta (3Y Monthly) | 2.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.32 |
| Earnings Date | Nov 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.50 |
- Thomson Reuters StreetEvents
Edited Transcript of VCEL earnings conference call or presentation 5-Nov-19 1:30pm GMT
Q3 2019 Vericel Corp Earnings Call
- Zacks
Stock Market News for Nov 6, 2019
Wall Street made nominal progress on Nov 5, given the record highs major indexes reached on Monday.
- GlobeNewswire
Vericel Announces Appointment of Sean C. Flynn as Vice President and General Counsel
Vericel Corporation (VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Sean C. Flynn as Vice President and General Counsel. Prior to joining Vericel, Mr. Flynn held the position of Vice President and General Counsel of Verastem, Inc., where he was responsible for all legal matters and supported the launch and commercialization of Copiktra®. Mr. Flynn also held the position of Associate General Counsel and Chief Compliance Officer for ABIOMED, Inc. during a period of rapid revenue and market growth.
- GlobeNewswire
Vericel Reports Record Third Quarter Revenues, Net Income and Operating Cash Flow
Product Revenues of $30.5 Million Increase 36% Over Third Quarter 2018Full Year 2019 Revenue Guidance Raised to $116 to $118 MillionConference Call Today at 8:30am Eastern Time.
- Simply Wall St.
How Much is Vericel Corporation's (NASDAQ:VCEL) CEO Getting Paid?
In 2013 Nick Colangelo was appointed CEO of Vericel Corporation (NASDAQ:VCEL). This analysis aims first to contrast...
- Insider Monkey
Is Vericel Corp (VCEL) Going To Burn These Hedge Funds ?
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Vericel Corp (NASDAQ:VCEL). Vericel Corp (NASDAQ:VCEL) was in 17 hedge […]
- GlobeNewswire
Vericel to Report Third-Quarter 2019 Financial Results on November 5, 2019
CAMBRIDGE, Mass., Oct. 22, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the.
- Benzinga
Vericel Analyst Projects Wound Care Product Sales Will Grow Fivefold By 2025
Vericel Corp (NASDAQ: VCEL ), a commercial-stage company that specializes in advanced cell therapies for treating patients with knee cartilage defects and severe burn wounds, is investment-worthy, according ...
- GlobeNewswire
Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol
Vericel Corporation (VCEL) and MediWound Ltd. (MDWD) today announced initiation of the NexoBrid® expanded access treatment protocol (NEXT) to treat burn patients with deep partial- and full-thickness burns in the U.S. during the preparation and review of the NexoBrid Biologics License Application (BLA). “We are excited to initiate NEXT in the U.S. in tandem with preparations with Vericel for the BLA filing,” said Sharon Malka, MediWound’s Chief Executive Officer.
- GlobeNewswire
Vericel to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019
CAMBRIDGE, Mass., Sept. 27, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that.
- Simply Wall St.
We're Excited To See How Vericel (NASDAQ:VCEL) Uses Its Cash Hoard To Grow
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- GlobeNewswire
Vericel to Present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019
CAMBRIDGE, Mass., Sept. 18, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that.
- GlobeNewswire
Vericel to Present at the 17th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019
CAMBRIDGE, Mass., Sept. 04, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that.
- Thomson Reuters StreetEvents
Edited Transcript of VCEL earnings conference call or presentation 6-Aug-19 12:00pm GMT
Q2 2019 Vericel Corp Earnings Call
Motley FoolVericel (VCEL) Q2 2019 Earnings Call Transcript
VCEL earnings call for the period ending June 30, 2019.
- Simply Wall St.
Is Vericel (NASDAQ:VCEL) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- GlobeNewswire
Vericel Reports Second Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance
Record Second Quarter Product Revenues of $26.2 Million Represent a 38% Increase Over Second Quarter 2018 Full Year 2019 Revenue Guidance Raised to $112 to $116 Million.
- GlobeNewswire
Vericel to Present at the 39th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019
CAMBRIDGE, Mass., Aug. 01, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that.
- GlobeNewswire
Vericel to Report Second-Quarter 2019 Financial Results on August 6, 2019
CAMBRIDGE, Mass., July 23, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced.
- Thomson Reuters StreetEvents
Edited Transcript of VCEL earnings conference call or presentation 7-May-19 12:00pm GMT
Q1 2019 Vericel Corp Earnings Call
- Simply Wall St.
Introducing Vericel (NASDAQ:VCEL), The Stock That Soared 736% In The Last Three Years
Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. You won't get...
- Simply Wall St.
Loss-Making Vericel Corporation (NASDAQ:VCEL) Expected To Breakeven
Vericel Corporation's (NASDAQ:VCEL): Vericel Corporation, a commercial-stage biopharmaceutical company, researches...
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Vericel Corp (VCEL)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- GlobeNewswire
BARDA to Fund NexoBrid Expanded Access Treatment Protocol for Thermal Burns
On May 7, 2019, Vericel announced that it had entered into exclusive license and supply agreements with MediWound Ltd. to commercialize NexoBrid in North America. NexoBrid is a topically-administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial- and full-thickness thermal burns within four hours of application without harming viable tissue. MediWound will receive the additional funding from BARDA under an amendment to an existing BARDA contract. Under the terms of the License Agreement, MediWound will continue to conduct all development activities under the supervision of a Central Steering Committee comprised of members of each party until the BLA is approved and subsequently transferred to Vericel. The NEXT protocol is an open-label, single-arm treatment protocol which allows for the treatment of up to 150 burn patients with deep partial- and full-thickness thermal burns up to 30% of total body surface area. Up to 30 sites will participate in the NEXT protocol. The protocol has been designed to be consistent with current real-life burn treatment practices in the U.S. The increased number of burn centers trained and familiar with NexoBrid prior to FDA approval and commercial availability will improve national readiness for potential burn mass casualty events. To further promote national readiness, the FDA has agreed that in the event of a burn mass casualty event that is not a nationally declared emergency, additional patients could be treated under the NEXT treatment protocol.
- GlobeNewswire
Vericel to Present at the 2019 UBS Global Healthcare Conference on Wednesday, May 22, 2019
CAMBRIDGE, Mass., May 15, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced.
